Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT00714740 Completed - Clinical trials for Obstructive Sleep Apnea Syndrome

Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

Start date: June 2008
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude

NCT ID: NCT00714298 Completed - Clinical trials for Acute Coronary Syndrome

Diagnostic Value of Heart-Fatty Acid Binding Protein and Ischemia Modified Albumin as Biochemical Markers on Non ST Segment Elevation Acute Coronary Syndrome at the Emergency Room.

Start date: May 2006
Phase: N/A
Study type: Interventional

Early diagnostic of non ST elevation coronary syndrome in patients admitted to the emergency room is difficult. Two news biochemical markers have been assessed and studies have suggested that heart fatty binding protein and ischemia modified albumin are early markers of myocardial necrosis and myocardial ischemia. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.

NCT ID: NCT00714233 Completed - Clinical trials for Polycystic Ovary Syndrome

Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)

Start date: August 2002
Phase: Phase 3
Study type: Interventional

A 24 week study to compare the use of Metformin, birth control pills and a carefully planned intensive lifestyle program that includes weight loss and exercise. These approaches will be compared to placebo (a pill that contains no active substances. Metformin, birth control pills and the lifestyle management program will be used on this research study to compare their ability to: 1. reduce fasting glucose levels 2. reduce androgen hormone levels 3. improve sex steroid binding, and 4. improve lipids (fatty substances in the blood)

NCT ID: NCT00711841 Terminated - HELLP Syndrome Clinical Trials

Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome

COHELLP
Start date: July 2011
Phase: Phase 4
Study type: Interventional

Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of blood products and shorter hospital stay.

NCT ID: NCT00710892 Active, not recruiting - Clinical trials for Acute Lymphoblastic Leukemia

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

CASPALLO
Start date: December 2008
Phase: Phase 1
Study type: Interventional

Patients are being asked to participate in this study because they will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, they will be given very strong doses of chemotherapy, which will kill off all their existing stem cells. Stem cells are created in the bone marrow. They grow into different types of blood cells that we need, including red blood cells, white blood cells, and platelets. We have identified a close relative of the patients whose stem cells are not a perfect match for the patient, but can be used. This type of transplant is called "allogeneic", meaning that the cells come from a donor. With this type of donor who is not a perfect match, there is typically an increased risk of developing graft-versus-host disease (GvHD) and a longer delay in the recovery of the immune system. GvHD is a serious and sometimes fatal side effect of stem cell transplant. GvHD occurs when the new donor cells recognize that the body tissues of the patient are different from those of the donor. In the laboratory, we have seen that cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. To get the iCasp9 into the T cells, we insert it using a virus called a retrovirus that has been made for this study. The drug (AP1903) that will be used to "activate" the iCasp9 is an experimental drug that has been tested in a study in normal donors, with no bad side effects. We hope we can use this drug to kill the T cells. Other drugs that kill or damage T cells have helped GvHD in many studies. However we do not yet know whether AP1903 will kill T cells in humans, even though it has worked in our experimental studies on human cells in animals. Nor do we know whether killing the T cells will help the GvHD. Because of this uncertainty, patients who develop significant GvHD will also receive standard therapy for this complication, in addition to the experimental drug. We hope that having this safety switch in the T cells will let us give higher doses of T cells that will make the immune system recover faster. These specially treated "suicide gene" T cells are an investigational product not approved by the Food and Drug Administration.

NCT ID: NCT00710073 Completed - Clinical trials for Chronic Pelvic Pain Syndrome

Sono-Electro-Magnetic Therapy for Refractory Chronic Pelvic Pain Syndrome

Start date: May 2006
Phase: N/A
Study type: Interventional

Treatment of chronic pelvic pain syndrome (CPPS) is challenging for patients and physicians once conventional therapies fail. We hypothesize that combined sono-electro-magnetic therapy can improve refractory CPPS in men.

NCT ID: NCT00709709 Completed - Coronary Syndrome Clinical Trials

Medical Evaluation of Scanner in Coronary Syndrome

EVASCAN
Start date: June 2006
Phase: N/A
Study type: Interventional

Many recent publications have reported encouraging results on diagnostic cardiac multislice CT performance in 1) coronary artery disease, 2) coronary arterial bypass graft potency and 3) intrastent restenosis. These single center studies were made on a limited number of patients (range, 50-130) and focused mainly on one of the indications mentioned above. Moreover, results were often given after exclusion of low quality examinations. At last, no study has compared the diagnostic performance of the different CT systems '16, 40 and 64) in these populations.

NCT ID: NCT00708747 Completed - Clinical trials for Systemic Inflammatory Response Syndrome

Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients

Start date: July 1996
Phase: Phase 4
Study type: Interventional

Morbidity and mortality in patients suffering from systemic inflammatory response syndrome (SIRS) remain high. The primary aim of the present study is to assess the efficacy of a standardized 5% serum-protein solution containing immunoglobulins on serum cytokine levels. The secondary aim is to evaluate survival of the patients.

NCT ID: NCT00706771 Completed - Renal Impairment Clinical Trials

Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study

BLISS
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The investigators will determine the feasibility, safety and efficacy of intravenous sodium bicarbonate in reducing progression to overt acute renal failure in patients with the systemic inflammatory response syndrome, and low urine output or early acute renal impairment as defined by serum neutrophil gelatinase-associated lipocalin (NGAL).

NCT ID: NCT00706758 Completed - Clinical trials for Irritable Bowel Syndrome

Structured Patient Education Versus Written Information for Patients With Irritable Bowel Syndrome

Start date: August 2004
Phase: N/A
Study type: Interventional

In this randomized controlled study in patients with irritable bowel syndrome (IBS) we plan to compare the effects of a structured patient group education (IBS school) with receiving only written information in the form of a IBS-guidebook. The effects of the interventions on GI and psychological symptom severity, knowledge and quality of life will be assessed with validated questionnaires at baseline and 3 and 6 months after the intervention.